2085. PrEP Interest and Preferences Among US Black and Hispanic Men – A National Survey

por Poteat, Tonia, Sarkar, Supriya, Ragone, Leigh, Rawlings, Keith, Rinehart, Alex R, Hill, Jennifer N, Gallington, Kyli, Coyne, Karin S, Vannappagari, Vani
Publicado 2022

1549. Risk Factors, Risk Perception, and Long-acting PrEP Awareness and Interest among US Women: A National Survey

por Poteat, Tonia, Sarkar, Supriya, Ragone, Leigh, Bogan, Danielle, Gallington, Kyli, Coyne, Karin S, Daniele, Patrick, Rawlings, Keith, Rinehart, Alex R, Vannappagari, Vani
Publicado 2023

2089. Relative patient preferences for starting daily, on-demand, and long-acting injectable HIV pre-exposure prophylaxis among US men who have sex with men, 2021-2022

por Sanchez, Travis, Wilson Beckham, S, Hannah, Marissa J, Winslow Edwards, O, Rawlings, Keith, Rinehart, Alex R, Sarkar, Supriya, Sullivan, Patrick S, Vannappagari, Vani
Publicado 2022

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment

por Stellbrink, Hans-Jürgen, Le Fevre, Eric, Carr, Andrew, Saag, Michael S., Mukwaya, Geoffrey, Nozza, Silvia, Valluri, Srinivas Rao, Vourvahis, Manoli, Rinehart, Alex R., McFadyen, Lynn, Fichtenbaum, Carl, Clark, Andrew, Craig, Charles, Fang, Annie F., Heera, Jayvant
Publicado 2016

Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study

por Seneviratne, Herana Kamal, Hamlin, Allyson N., Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y., Kuo, Irene, Hosseinipour, Mina C., Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Adeyeye, Adeola, Rinehart, Alex R., McCauley, Marybeth, Eron, Joseph S., Cohen, Myron S., Landovitz, Raphael J., Hendrix, Craig W., Bumpus, Namandjé N.
Publicado 2021

Correction to “Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study”

por Seneviratne, Herana Kamal, Hamlin, Allyson N., Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y., Kuo, Irene, Hosseinipour, Mina C., Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Adeyeye, Adeola, Rinehart, Alex R., McCauley, Marybeth, Eron, Joseph J., Cohen, Myron S., Landovitz, Raphael J., Hendrix, Craig W., Bumpus, Namandjé N.
Publicado 2021

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

por Landovitz, Raphael J., Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y., Magnus, Manya, Hosseinipour, Mina C., Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Richardson, Paul, Marzinke, Mark A., Hendrix, Craig W., Eshleman, Susan H., Zhang, Yinfeng, Tolley, Elizabeth, Sugarman, Jeremy, Kofron, Ryan, Adeyeye, Adeola, Burns, David, Rinehart, Alex R., Margolis, David, Spreen, William R., Cohen, Myron S., McCauley, Marybeth, Eron, Joseph J.
Publicado 2018

Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083

por Marzinke, Mark A., Fogel, Jessica M., Wang, Zhe, Piwowar-Manning, Estelle, Kofron, Ryan, Moser, Amber, Bhandari, Pradip, Gollings, Ryann, Bushman, Lane R., Weng, Lei, Halvas, Elias K., Mellors, John, Anderson, Peter L., Persaud, Deborah, Hendrix, Craig W., McCauley, Marybeth, Rinehart, Alex R., St Clair, Marty, Ford, Susan L., Rooney, James F., Adeyeye, Adeola, Chariyalertsak, Suwat, Mayer, Kenneth, Arduino, Roberto C., Cohen, Myron S., Grinsztejn, Beatriz, Hanscom, Brett, Landovitz, Raphael J., Eshleman, Susan H.
Publicado 2023